H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)

March 19, 2025 6:43 AM

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating and $12.50 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found